Clinical Trial Search

Primary: Change in Hearing In Noise Test Score in Quiet (HINT-Q) From Baseline to 6 Months in English-speaking Participants. — 51.5 percent change words correctly repeated

Primary: Inflammatory Lesion Counts — -29.9; -26.7; -24.8; -26.8 lesions

Primary: Percentage of Words Identified Before and After Training — 49.7; 55.7 percentage of words presented

Primary: Time to Prostate Cancer Progression — NA; NA Months — p=0.016

Primary: Number of Participants With Adverse Events — 5; 3; 28 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device — 18; 15 percentage difference — p=0.210

Primary: Receipt of Any Reproductive Health Counseling — 54; 38 Participants

Primary: Number of Participants With Medication Related (Thromboembolic) Complications — 0 Participants

Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001

Primary: Number of Participants With Treatment-related Adverse Events and Dosing Symptoms Occurring With Peanut OIT Over a Protracted Treatment Period Comprising at Least 18…

Primary: Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8. — 2057.0; 1116.2; 1465.3; 2023.8 titer — p=0.0015

Primary: Soluble P-selectin Level — 7; 39 ng/mL

Primary: Actigraphy Data — 72; 76; 76; 77 percentage of sleep efficiency (0-100) — p=.955

Primary: Time From Initiation of Adjunctive Therapy Until Hospital Discharge — 20; 33.8 Days